Showing results (931-940 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|August 27, 2021
Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin-Releasing Hormone Antagonist, in Healthy Adult SubjectsCarol M MacLean, Zona Godsafe, Pablo Soto-Forte, et al.
Clinical Pharmacology in Drug Development|September 4, 2021
Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy AdultsKimberly A Ramos, Ian E James, Franck Skobieranda, et al.
Clinical Pharmacology in Drug Development|August 26, 2022
Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese SubjectsTing Li, Feifei Sun, Yanping Liu, et al.
Clinical Pharmacology in Drug Development|May 28, 2020
Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 StudyMasahiro Nomoto, Atsushi Takeda, Katsuaki Iwai, et al.
Clinical Pharmacology in Drug Development|May 17, 2020
Pharmacokinetics and Bioequivalence Evaluation of Erlotinib Hydrochloride Tablets: Randomized, Open-Label, 2-Period Crossover Study in Healthy Chinese SubjectsLu Wang, Zourong Ruan, Dandan Yang, et al.
Clinical Pharmacology in Drug Development|May 6, 2021
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult SubjectsHidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, et al.
Clinical Pharmacology in Drug Development|May 6, 2021
Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 StudiesJulie Desrivot, Tim Van Kaem, Lisa Allamassey, et al.
Clinical Pharmacology in Drug Development|August 24, 2021
Randomized, Double-Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult VolunteersTosei Murase, Masaomi Takizawa, Lawrence Galitz, et al.
Clinical Pharmacology in Drug Development|January 19, 2026
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 StudiesAndrew C Vendel, Olivier Benichou, Ching-Yun Chang, et al.
Clinical Pharmacology in Drug Development|January 19, 2026
A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy VolunteersVipul K Gupta, Brian Yoo, Daniel Weiss, et al.
Pageof 136